Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1999 | 1 |
2005 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
The following term was ignored: [letter comment
Page 1
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22.
Lancet Gastroenterol Hepatol. 2024.
PMID: 38402895
Free PMC article.
Clinical Trial.
METHODS: PROFILE (PRedicting Outcomes For Crohn's disease using a moLecular biomarker) was a multicentre, open-label, biomarker-stratified, randomised controlled trial that enrolled adults with newly diagnosed active Crohn's disease (Harvey-Bradshaw Index 7, either elevated C-rea …
METHODS: PROFILE (PRedicting Outcomes For Crohn's disease using a moLecular biomarker) was a multicentre, open-label, biomarker-stratified, …
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.
Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ.
Lowry PW, et al.
Gastroenterology. 1999 Jun;116(6):1505-6. doi: 10.1016/s0016-5085(99)70524-x.
Gastroenterology. 1999.
PMID: 10391741
No abstract available.
Item in Clipboard
Review article: practical management of inflammatory bowel disease patients taking immunomodulators.
Siegel CA, Sands BE.
Siegel CA, et al.
Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16. doi: 10.1111/j.1365-2036.2005.02520.x.
Aliment Pharmacol Ther. 2005.
PMID: 15963074
Free article.
Review.
These immunomodulators are potent and effective medications; however, they potentially have serious toxicity. To maximize benefit and minimize risk, clinicians must understand the mechanism of action, appropriate indications, range of toxicity and proper dosing of t …
These immunomodulators are potent and effective medications; however, they potentially have serious toxicity. To maximize bene …
Item in Clipboard
Cite
Cite